Insys Eyes Sale of Opioid-Related Assets, Including Subsys

Insys Eyes Sale of Opioid-Related Assets, Including Subsys

Source: 
BioSpace
snippet: 

Months after the U.S. Food and Drug Administration (FDA) rejected Insys Therapeutics’ buprenorphine sublingual spray for moderate-to-severe acute pain, the Arizona-based company is assessing strategic alternatives for its opioid-related assets as it continues to shift its focus to a new therapeutic – cannabinoids.